Citations

Clear

168 citation(s) found for "Perlmutter, J".

Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Gonzalez‐Kozlova, Edgar , Huang, Hsin-Hui , Jagede, Opeyemi A. , Tuballes, Kevin , Valle, Diane M. Del , Kelly, Geoffrey , Patel, Manishkumar , Xie, Hui , Harris, Jocelyn , Argueta, Kimberly , Nie, Kai , Barcessat, Vanessa , Moravec, Radim , Ansell, Stephen M. , Yu, Joyce , Cerami, Ethan , Lindsay, James , Wistuba, Ignacio I. , Gnjatic, Sacha , Jegede, Opeyemi A. , Del Valle, Diane M , Altreuter, Jennifer , Duose, Dzifa Y , Kahl, Brad S , Ansell, Stephen M , Yu, Joyce , Cerami, Ethan , Lindsay, James R , Wistuba, Ignacio I , Kim-Schulze, Seunghee , Diefenbach, Catherine S , Gnjatic, Sacha , Kahl, Brad S. , Diefenbach, Catherine

Mayo Clinic

Cancer Research Communications | June 27, 2024 | Volume: 4 | Issue: 7 | Pages: 1726-1737

10.1158/2767-9764.crc-24-0252 | PMID 38934093 Get It

Abstract To investigate the cellular and molecular mechanisms associated with targeting CD30-expressing Hodgkin lymphoma (HL) and immune checkpoint modulation induced by combination therapies of CTLA4 and PD1, we leveraged Phase 1/2 multicenter open-label trial NCT01896999 that enrolled patients with refractory or relapsed HL (R/R HL). Using peripheral blood, we assessed soluble proteins, cell composition, T-cell clonality, and tumor antigen-specific antibodies in 54 patients enrolled in the phase 1 component of the trial. NCT01896999 reported high (>75%) overall objective response rates with brentuximab vedotin (BV) in combination with ipilimumab (I) and/or nivolumab (N) in patients with R/R HL. We observed a durable increase in soluble PD1 and plasmacytoid dendritic cells as well as decreases in plasma CCL17, ANGPT2, MMP12, IL13, and CXCL13 in N-containing regimens (BV + N and BV + I + N) compared with BV + I (P < 0.05). Nonresponders and patients with short progression-free survival showed elevated CXCL9, CXCL13, CD5, CCL17, adenosine–deaminase, and MUC16 at baseline or after one treatment cycle and a higher prevalence of NY-ESO-1-specific autoantibodies (P < 0.05). The results suggest a circulating tumor-immune-derived signature of BV ± I ± N treatment resistance that may be useful for patient stratification in combination checkpoint therapy. Significance: Identification of multi-omic immune markers from peripheral blood may help elucidate resistance mechanisms to checkpoint inhibitor and antibody–drug conjugate combinations with potential implications for treatment decisions in relapsed HL.
Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk
Ni, Zhanmo , Kundu, Prosenjit , McKean, David , Wheeler, William , Albanes, Demetrius , Andreotti, Gabriella , Antwi, Samuel O. , Arslan, Alan A. , Bamlet, William R. , Freeman, Laura E. Beane , Berndt, Sonja I. , Bracci, Paige M. , Brennan, Paul , Buring, Julie E. , Gallinger, Steven , Gaziano, J. Michael , Giovannucci, Edward L. , Goodman, Phyllis J. , Haiman, Christopher A. , Hassan, Manal M. , Holly, Elizabeth A. , Li, Donghui , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Visvanathan, Kala , White, Emily , Wolpin, Brian M. , Zhong, Jun, McKean, David F , Beane Freeman, Laura E , Chanock, Stephen Jacob , Gallinger, Steven , Gaziano, J Michael , Giles, Graham G , Giovannucci, Edward L , Goggins, Michael G , Goodman, Phyllis J , Haiman, Christopher A , Hassan, Manal M , Holly, Elizabeth A , Hung, Rayjean J , Katzke, Verena , Kooperberg, Charles , Kraft, Peter , Marchand, Loïc Le , Li, Donghui , McCullough, Marjorie L , Milne, Roger L , Moore, Steven C , Neale, Rachel E , Oberg, Ann L , Patel, Alpa V , Peters, Ulrike , Chaffee, Kari G. , Risch, Harvey A , Shu, Xiao-Ou , Smith-Byrne, Karl , Visvanathan, Kala , Wactawski-Wende, Jean , White, Emily , Wolpin, Brian M , Yu, Herbert , Zeleniuch-Jacquotte, Anne , Zheng, Wei , Zhong, Jun , Amundadottir, Laufey , Stolzenberg-Solomon, Rachael , Klein, Alison P , Antwi, Samuel O , Arslan, Alan A , Bamlet, William R , Albanes, Demetrius , Giles, Graham G. , Goggins, Michael , Hung, Rayjean J. , Kooperberg, Charles , Kraft, Peter , Marchand, Loı̈c Le , McCullough, Marjorie L. , Milne, Roger L. , Moore, Steven C. , Neale, Rachel Ε. , Rabe, Kari G. , Risch, Harvey A. , Shu, Xiao‐Ou , Wactawski‐Wende, Jean , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Zheng, Wei , Ámundadóttir, Laufey T. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 13, 2024 | Volume: 33 | Issue: 9 | Pages: 1229-1239

10.1158/1055-9965.epi-24-0096 | PMID 38869494 Get It

Abstract Background: Pancreatic cancer is a leading cause of cancer-related death globally. Risk factors for pancreatic cancer include common genetic variants and potentially heavy alcohol consumption. We assessed if genetic variants modify the association between heavy alcohol consumption and pancreatic cancer risk. Methods: We conducted a genome-wide interaction analysis of single-nucleotide polymorphisms (SNP) by heavy alcohol consumption (more than three drinks per day) for pancreatic cancer in European ancestry populations from genome-wide association studies. Our analysis included 3,707 cases and 4,167 controls from case–control studies and 1,098 cases and 1,162 controls from cohort studies. Fixed-effect meta-analyses were conducted. Results: A potential novel region of association on 10p11.22, lead SNP rs7898449 (interaction P value (Pinteraction) = 5.1 × 10−8 in the meta-analysis; Pinteraction = 2.1 × 10−9 in the case–control studies; Pinteraction = 0.91 in the cohort studies), was identified. An SNP correlated with this lead SNP is an expression quantitative trait locus for the neuropilin 1 gene. Of the 17 genomic regions with genome-wide significant evidence of association with pancreatic cancer in prior studies, we observed suggestive evidence that heavy alcohol consumption modified the association for one SNP near LINC00673, rs11655237 on 17q25.1 (Pinteraction = 0.004). Conclusions: We identified a novel genomic region that may be associated with pancreatic cancer risk in conjunction with heavy alcohol consumption located near an expression quantitative trait locus for neuropilin 1, a protein that plays an important role in the development and progression of pancreatic cancer. Impact: This work can provide insights into the etiology of pancreatic cancer, particularly in heavy drinkers.
Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy
Azim, Hatem A. , Niman, Samuel M. , Partridge, Ann H. , Demeestere, Isabelle , Ruggeri, Monica , Colleoni, Marco , Saura, Cristina , Shimizu, Chikako , Sætersdal, Anna Barbro, Kroep, Judith R. , Mailliez, Audrey , Gombos, Andrea, Kataoka, Akemi, Rousset‐Jablonski, Christine , Borštnar, Simona , Takei, Junko , Walshe, Janice M. , Ruíz-Borrego, Manuel , Bjelic‐Radisic, Vesna , Klar, Natalie , Španić, Tanja, Ruddy, Kathryn J. , Piccart, Martine , Korde, Larissa A. , Goldhirsch, Aron, Gelber, Richard D. , Pagani, Olivia , Borges, Virginia F , Amant, Frederic , Kataoka, Akemi , Rousset-Jablonski, Christine , Takei, Junko , Lee, Jeong Eon , Walshe, Janice M , Ruíz-Borrego, Manuel , Moore, Halle C F , Saunders, Christobel , Susnjar, Snezana , Cardoso, Fatima , Klar, Natalie J , Ruddy, Kathryn J , Piccart, Martine , Goldhirsch, Aron , Gelber, Richard D , Peccatori, Fedro A , Partridge, Ann H , Demeestere, Isabelle , Colleoni, Marco , Saura, Cristina , Warner, Ellen , Borges, Virginia F. , Amant, Frédéric , Gombos, Andrea , Moore, Halle C. F. , Saunders, Christobel , Cardoso, Fátima

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 23 | Pages: 2822-2832

10.1200/jco.23.02292 | PMID 38810178 Get It

PURPOSE We investigated time to pregnancy, efficacy and safety of fertility preservation, and assisted reproductive technologies (ARTs) in women with early hormone receptor–positive breast cancer (BC) desiring future pregnancy. PATIENTS AND METHODS POSITIVE is an international, single-arm, prospective trial, in which 518 women temporarily interrupted adjuvant endocrine therapy to attempt pregnancy. We evaluated menstruation recovery and factors associated with time to pregnancy and investigated if ART use was associated with achieving pregnancy. The cumulative incidence of BC-free interval (BCFI) events was estimated according to the use of ovarian stimulation at diagnosis. The median follow-up was 41 months. RESULTS Two hundred seventy-three patients (53%) reported amenorrhea at enrollment, of whom 94% resumed menses within 12 months. Among 497 patients evaluable for pregnancy, 368 (74%) reported at least one pregnancy. Young age was the main factor associated with shorter time to pregnancy with cumulative incidences of pregnancy by 1 year of 63.5%, 54.3%, and 37.7% for patients age <35, 35-39, and 40-42 years, respectively. One hundred and seventy-nine patients (36%) had embryo/oocyte cryopreservation at diagnosis, of whom 68 reported embryo transfer after enrollment. Cryopreserved embryo transfer was the only ART associated with higher chance of pregnancy (odds ratio, 2.41 [95% CI, 1.75 to 4.95]). The cumulative incidence of BCFI events at 3 years was similar for women who underwent ovarian stimulation for cryopreservation at diagnosis, 9.7% (95% CI, 6.0 to 15.4), compared with those who did not, 8.7% (95% CI, 6.0 to 12.5). CONCLUSION In POSITIVE, fertility preservation using ovarian stimulation was not associated with short-term detrimental impact on cancer prognosis. Pregnancy rates were highest among those who underwent embryo/oocyte cryopreservation followed by embryo transfer.
Abstract GS02-11: Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
Azim, Hatem A. , Niman, Samuel, Ruggeri, Monica , Saura, Cristina , Shimizu, Chikako , Sætersdal, Anna Barbro, Mailliez, Audrey , Gombos, Andrea, Kataoka, Akemi, Borštnar, Simona , Takei, Junko , Lee, Jeong Eon, Borrego, Manuel Ruíz, Bjelic‐Radisic, Vesna , Klar, Natalie , Spanic, Tanya, Ruddy, Kathryn, Piccart, Martine , Korde, Larissa A. , Goldhirsch, Aron, Gelber, Richard D. , Pagani, Olivia , Klar, Natalie J , Saura, Cristina , Partridge, Ann H. , Demeestere, Isabelle , Colleoni, Marco , Kroep, Judith R. , Warner, Ellen , Borges, Virginia F. , Amant, Frédéric , Gombos, Andrea , Rousset‐Jablonski, Christine , Lee, Jeong Eon, Walshe, Janice M. , Moore, Halle C. F. , Saunders, Christobel , Susnjar, Snezana , Cardoso, Fátima , Ruddy, Kathryn J. , Peccatori, Fedro A

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: GS02-11-GS02-11

10.1158/1538-7445.sabcs23-gs02-11 Get It

Abstract Background: The POSITIVE trial recently demonstrated that temporary interruption of ET to attempt pregnancy does not increase the short-term risk of recurrence in pts with hormone receptor-positive (HR+) BC. Yet, uncertainty exists regarding the safety of ovarian stimulation for embryo/oocyte cryopreservation to preserve fertility in these pts. In addition, very limited data exist regarding safety and efficiency of ART to achieve pregnancy after ET interruption. Methods: POSITIVE is an international, single-arm, prospective trial that enrolled pts ≤ 42 years with stage I-III HR+ BC who had already received 18-30 months of ET prior to enrollment. The use of ART was a predefined 2ry endpoint. We evaluated factors associated with time to pregnancy in a Fine and Gray competing risks model, which included chemotherapy (chemo) ± GnRH analogue (GnRHa), age, prior ET, prior birth, and menstrual status at enrollment. The cumulative incidence of pregnancy at 12 months from enrollment by age was estimated controlling for competing risks. We performed a logistic regression model to evaluate whether ART use was associated with achieving pregnancy, adjusting for age, receipt of chemo ± GnRHa. The cumulative incidence of BCFI events was estimated according to whether or not ovarian stimulation for cryopreservation was performed at diagnosis and prior to enrollment. BC-free interval (BCFI) was defined as the time from enrollment until the first BC event (invasive local, regional, or distant recurrence or contralateral disease). A 24-month landmark analysis was performed to investigate the safety of ART use after enrollment. Median follow-up was 41 months. Results: 497 out of 516 included pts (96%) were followed for at least 6 months and were evaluable for pregnancy status. 368 out of 497 evaluable pts (74%) reported at least one pregnancy. In a multivariable model, young age was the only factor associated with shorter time to pregnancy. The cumulative incidence of pregnancy at 12 months was 64%, 54% and 38% for pts aged &lt; 35, 35-39 and 40-42 years, respectively. 179 pts (36.0%) had undergone ovarian stimulation for embryo/oocyte cryopreservation at diagnosis and prior to enrollment, of whom 68 (37.9%) reported cryopreserved embryo transfer after enrollment. 215 pts (43.3%) reported using any ART after enrollment, of whom 80 (37.2%) underwent ovarian stimulation for in-vitro fertilization (FIVET) or intracytoplasmic sperm injection (ICSI). Other ART used included clomiphene (n=19), intrauterine insemination (n=37) and egg donation (n=17). Pregnancy rates were 82.4% and 67.5% for women who underwent cryopreserved embryo transfer and FIVET/ICSI, respectively. In a multivariate model, cryopreserved embryo transfer was the only ART independently associated with a higher chance of pregnancy (OR:2.41, 95% CI: 1.75-4.95). The cumulative incidence of BCFI events at 3 years was similar for women who underwent ovarian stimulation for cryopreservation at diagnosis and before enrollment, 9.7% (95% CI: 6.0-15.4%), and those who did not, 8.7% (95% CI: 6.0-12.5%). A 24-month landmark analysis showed no impact of ovarian stimulation for FIVET/ICSI after enrollment on BCFI. Conclusions: This is the largest prospective study to investigate fertility preservation and ART in pts with HR+ BC. Young age was the main factor associated with shorter time to pregnancy. Embryo/oocyte cryopreservation at BC diagnosis followed by embryo transfer after ET interruption was the only approach associated with an increased chance of pregnancy. Ovarian stimulation either at BC diagnosis for embryo/oocyte cryopreservation or after enrollment to POSITIVE for FIVET/ICSI did not appear to impact prognosis in the short term. These data are of paramount importance for oncofertility counselling of young BC pts. Citation Format: Hatem Azim, Samuel Niman, Ann Partridge, Isabelle Demeestere, Monica Ruggeri, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Saetersdal, Judith Kroep, Audrey Mailliez, Ellen Warner, Virginia Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong Eon Lee, Janice Walshe, Manuel Ruíz - Borrego, Halle Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Natalie Klar, Tanya Spanic, Kathryn Ruddy, Martine Piccart, Larissa Korde, Aron Goldhirsch, Richard Gelber, Olivia Pagani, Fedro Alessandro Peccatori. Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr GS02-11.
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer
Yaeger, Rona , Uboha, Nataliya V. , Pelster, Meredith S. , Bekaii‐Saab, Tanios , Barve, Minal , Saltzman, Joel , Sabari, Joshua K. , Peguero, Julio A. , Paulson, Andrew Scott , Jänne, Pasi A. , Anderes, Kenna , Velastegui, Karen , Yan, Xiaohong , Der‐Torossian, Hirak , Bekaii-Saab, Tanios S , Cruz-Correa, Marcia , Anderes, Kenna , Velastegui, Karen , Yan, Xiaohong , Der-Torossian, Hirak , Klempner, Samuel J , Kopetz, Scott , Cruz‐Correa, Marcia , Klempner, Samuel J. , Kopetz, Scott

Mayo Clinic

Cancer Discovery | April 8, 2024 | Volume: 14 | Issue: 6 | Pages: 982-993

10.1158/2159-8290.cd-24-0217 | PMID 38587856 Get It

Abstract Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897 See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4
Abstract 1207: Immune subtyping identifies a subset of HR+HER2- early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO arms of the I-SPY2 TRIAL
Nanda, Rita , Chien, Jo, Stringer-Reasor, Erica , Liu, Minetta C. , Soliman, Hatem , Campbell, Michael J. , Barcaru, Andrei, Kuilman, Midas M. , Hirst, Gillian L. , Beineke, Philip, Investigators, I-SPY2, Perlmutter, Jane , Rugo, Hope, Clark, Amy S. , Pohlmann, Paula R. , Veer, Laura van ‘t , Hirst, Gillian L , Pohlmann, Paula , Wolf, Denise M. , Yau, Christina , Pusztai, Lajos , Shatsky, Rebecca , Isaacs, Claudine , Han, Hyo S , Glas, Annuska M. , Mittempergher, Lorenza , Swigart, Lamorna Brown , Yu, Hongmei , Basu, Amrita B , Investigators, I-SPY2, Yee, Douglas , Symmans, W. Fraser , DeMichele, Angela , Delson, Amy , Huppert, Laura Ann , Hylton, Nola M. , Esserman, Laura J. , Veer, Laura J. van’t

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 1207-1207

10.1158/1538-7445.am2024-1207 Get It

Abstract Background: Neoadjuvant immunotherapy (IO) has become standard of care for early-stage triple negative breast cancer (TNBC). I-SPY2 was the first randomized trial to examine the efficacy of IO therapy in high-risk HR+HER2- breast cancer, where most IO arms showed improved efficacy relative to control. We also previously showed immune-gene expression signatures associate with pathologic complete response (pCR) in HR+HER2- treated with IO; and developed a clinically applicable Immune classifier (ImPrint) predicting response to IO that is now being used in I-SPY2.2 as part of the Response Predictive Subtypes. Here we report the performance of ImPrint in HR+HER2- patients from 5 IO arms. Methods: 204 HR+HER2- (MammaPrint high risk) patients from 5 IO arms (anti-PD1, anti-PDL1/PARPi, anti-PD1/TLR9 dual-IO, and anti-PD1 +/- LAG3 dual-IO) and 191 patients from the control arm were included in this analysis. Patients were classified ImPrint+ (likely sensitive) vs. ImPrint- (likely resistant), by Agendia, Inc, using pre-treatment mRNA. Performance of ImPrint for predicting pCR to IO was characterized and compared to that of MammaPrint (ultra) High2 risk (MP2) and tumor grade (III). Based on the DRFS of pCR vs. non-pCR HR+HER2-/ImPrint+ patients (median follow up ~4.5yr), we predicted the DRFS in the IO vs. control arms using an exponential model as a function of the pCR rates. Results: Overall, the pCR rate over the 5 IO arms was 33%. 28% of HR+HER2- patients were ImPrint+; and pCR rates with IO were 76% in ImPrint+ vs. 16% in ImPrint-, with the highest pCR rate &gt;90% in a dual-IO arm. In the control arm, pCR rates were 33% in ImPrint+ and 8% in ImPrint-. Based on the pCR rates in the IO vs. control (76% vs. 33%), the predicted DRFS of HR+HER2-/ImPrint+ patients are 91% vs 80% at 5 years, respectively. This translates to a risk reduction of 52% for the IO arm relative to standard chemotherapy in HR+HER2-/ImPrint+ patients. We also compared MP2 and tumor grade (III) to ImPrint+ as pCR predictors, as these markers have been used or proposed as selection markers for neoadjuvant IO trials in HR+HER2-. The pCR rates for MP2, Grade III, at 56%, 45%, respectively, are much smaller than that for ImPrint+ at 75% pCR; thus ImPrint appears to be a more precise predictive biomarker for neoadjuvant IO therapy in the HR+HER2- breast cancers. Conclusion: These results suggest that a subset of high risk HR+HER2- breast cancers is highly sensitive to immunotherapy, and by using a specific and sensitive selection strategy patients could achieve pCR rates similar to what is seen with best neoadjuvant therapies in TNBC and HER2+ (i.e., pCR rate &gt; 65-70%). ImPrint, an FDA IDE-enabled assay currently being further evaluated in I-SPY2, may represent the way to identify patients for IO that best balances likely benefit vs risk of serious immune-related adverse events. Citation Format: Denise M. Wolf, Christina Yau, Lajos Pusztai, Rita Nanda, Jo Chien, Erica Stringer-Reasor, Rebecca Shatsky, Claudine Isaacs, MInetta Liu, Hyo Han, Hatem Soliman, Michael Campbell, Annuska Glas, Andrei Barcaru, Lorenza Mittempergher, Midas Kuilman, Lamorna Brown Swigart, Gillian Hirst, Hongmei Yu, Philip Beineke, Amrita Basu, I-SPY2 Investigators, Douglas Yee, W. Fraser Symmans, Angela DeMichele, Jane Perlmutter, Amy Delson, Laura Huppert, Hope Rugo, Amy Clark, Nola Hylton, Paula Pohlmann, Laura Esserman, Laura van 't Veer. Immune subtyping identifies a subset of HR+HER2- early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO arms of the I-SPY2 TRIAL [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1207.
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Ghobrial, Irene M. , Kumar, Shaji , Mateos, María‐Victoria , Bergsagel, P. Leif , Chesi, Marta , Dhodapkar, Madhav V. , Getz, Gad , Manier, Salomon , Nuvolone, Mario , O’Donnell, Elizabeth , Sklavenitis‐Pistofidis, Romanos , Sperling, Adam S. , Vassiliou, George S. , Munshi, Nikhil C. , Bergsagel, P. Leif , Gormley, Nicole , Kumar, Shaji K , Mateos, María-Victoria , Chesi, Marta , Dhodapkar, Madhav V , Getz, Gad , Kastritis, Efstathios , Kristinsson, Sigurdur Y , Martinez-Climent, Jose Angel , Manier, Salomon , Marinac, Catherine R , Maura, Francesco , Morgan, Gareth J , Davies, Faith E , Nadeem, Omar , Nuvolone, Mario , Paiva, Bruno , O'Donnell, Elizabeth , Prosper, Felipe , Shah, Urvi A , Sklavenitis-Pistofidis, Romanos , Sperling, Adam S , Munshi, Nikhil C , Castle, Philip E , Anderson, Kenneth C , San-Miguel, Jesus , Ghobrial, Irene M , Gormley, Nicole , Dispenzieri, Angela , Fonseca, Rafaël , Kastritis, Efstathios , Martinez‐Climent, José A. , Marinac, Catherine R. , Maura, Francesco , Morgan, Gareth J. , Davies, Faith E. , Nadeem, Omar , Paiva, Bruno , Prósper, Felipe , Shah, Urvi A. , Anderson, Kenneth C. , Miguel, Jesús F. San

Mayo Clinic

Blood Cancer Discovery | March 5, 2024 | Volume: 5 | Issue: 3 | Pages: 146-152

10.1158/2643-3230.bcd-24-0022 | PMID 38441243 Get It

Summary: While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Jahangir, Chowdhury Arif , Page, David B. , Broeckx, Glenn , Gonzalez, Claudia Aura, Burke, Caoimbhe, Murphy, Clodagh, Reis‐Filho, Jorge S. , Gupta, Rajarsi , Vieth, Michael, Hida, Akira I. , Kahila, Mohamed M. , Kos, Zuzana , Verbandt, Sara , Thagaard, Jeppe , Khiroya, Reena, Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Portela, Flávio Luis Dantas , Deman, Frederik , Dudgeon, Sarah , Elghazawy, Mahmoud , Fernandez‐Martín, Claudio , Fineberg, Susan , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hartman, Johan , Hewitt, Stephen M. , Husain, Zaheed, Irshad, Sheeba , Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Khramtsov, Andrey , Kirtani, Pawan , Korski, Konstanty, Scott, Ely, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Durga, Kharidehal, Mittal, Shachi , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Hytopoulos, Evangelos, Mahon, Sarah, Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Verghese, Gregory , Viale, Giuseppe , Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Bartlett, John M.S. , Loibl, Sibylle , Loi, Sherene , Stovgaard, Elisabeth Specht , Salgado, Roberto , Gupta, Rajarsi R , Chardas, Alexandros , Dantas Portela, Flavio Luis , Elghazawy, Mahmoud , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Hart, Steven N , Hartman, Johan , Kataoka, Tatsuki R , Rau, Tilman T , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Lennerz, Jochen , Loi, Sherene , Reis-Filho, Jorge S , Acs, Balazs , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , Ly, Amy , Harms, Paul W. , Diest, P. J. van , AbdulJabbar, Khalid , Adams, Sylvia , Almeida, Jonas S. , Ardalan, Farid Azmoudeh , Badve, Sunil , Hardas, Alexandros , Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Janssen, Emiel A. M. , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Aktürk, Güray , Kovács, Anikó , Lerousseau, Marvin , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Moore, David , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rajpoot, Nasir , Rapoport, Bernardo L. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sughayer, Maher A. , Sur, Daniel Genel , Symmans, W. Fraser , Teuwen, Jonas , Tran, William T, Laak, Jeroen van der , Yuan, Yinyin , Denkert, Carsten , Savas, Peter Stephen , Gallagher, William M. , Rahman, Arman

Mayo Clinic

The Journal of Pathology | January 17, 2024 | Volume: 262 | Issue: 3 | Pages: 271-288

10.1002/path.6238 | PMID 38230434 Get It

Abstract Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high‐throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi‐marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Maura, Francesco , Rajanna, Arjun Raj , Ziccheddu, Bachisio , Poos, Alexandra M. , Derkach, Andriy , Maclachlan, Kylee , Durante, Michael , Diamond, Benjamin , Papadimitriou, Marios , Davies, Faith E. , Boyle, Eileen M. , Walker, Brian A. , Hultcrantz, Malin , Silva, Ariosto, Hampton, Oliver , Teer, Jamie K. , Siegel, Erin M. , Bolli, Niccolò , Jackson, Graham , Kaiser, Martin , Cook, Gordon , Kazandjian, Dickran , Stein, Caleb, Chesi, Marta , Bergsagel, Leif, Elias, K. , Goldschmidt, Hartmut , Fenk, Roland , Rhee, Fritz Van, Usmani, Saad Z. , Shain, Kenneth H. , Weinhold, Niels , Bergsagel, P. Leif , Bergsagel, P. Leif , Davies, Faith E , Walker, Brian A , Jackson, Graham H , Pawlyn, Charlotte , Cook, Gordon , Kazandjian, Dickran , Chesi, Marta , Mai, Elias K , Goldschmidt, Hartmut , Weisel, Katja C , Fenk, Roland , Raab, Marc S , van Rhee, Frits , Usmani, Saad , Shain, Kenneth H , Weinhold, Niels , Landgren, C Ola , Bolli, Niccolo' , Boyle, Eileen M , Kaiser, Martin F , Maura, Francesco , Durante, Michael , Maclachlan, Kylee , Derkach, Andriy , Diamond, Benjamin T , Pawlyn, Charlotte , Stein, Caleb, Raab, Marc S. , Morgan, Gareth J. , Landgren, Ola

Mayo Clinic

Journal of Clinical Oncology | January 9, 2024 | Volume: 42 | Issue: 11 | Pages: 1229-1240

10.1200/jco.23.01277 | PMID 38194610 Get It

PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0.572), and R2-ISS (0.625). Integral to model accuracy was 20 genomic features, including 1q21 gain/amp, del 1p, TP53 loss, NSD2 translocations, APOBEC mutational signatures, and copy-number signatures (reflecting the complex structural variant chromothripsis). IRMMa accuracy and superiority compared with other prognostic models were validated on 256 patients enrolled in the GMMG-HD6 (ClinicalTrials.gov identifier: NCT02495922 ) clinical trial. Individualized patient risks were significantly affected across the 12 genomic groups by different treatment strategies (ie, treatment variance), which was used to identify patients for whom HDM-ASCT is particularly effective versus patients for whom the impact is limited. CONCLUSION Integrating clinical, demographic, genomic, and therapeutic data, to our knowledge, we have developed the first individualized risk-prediction model enabling personally tailored therapeutic decisions for patients with NDMM.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Albain, Kathy S. , Yau, Christina , Petricoin, Emanuel F. , Wolf, Denise M. , Lang, Julie E. , Chien, A. Jo , Haddad, Tufia C. , Forero-Torres, Andres , Wallace, Anne M. , Kaplan, Henry G. , Euhus, David , Nanda, Rita , Clark, Amy S. , Godellas, Constantine , Tripathy, Debu , Lu, Janice , Yung, Rachel L. , Wulfkuhle, Julia , Krings, Gregor , Chen, Yunn‐Yi , Potter, David A. , Stringer-Reasor, Erica , Blair, Sarah L. , Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L. , Sanil, Ashish, Matthews, Jeffrey B. , Melisko, Michelle , Perlmutter, Jane , Symmans, W. Fraser , Veer, Laura J. van’t , Yee, Douglas , Berry, Donald A. , Haddad, Tufia C , Kaplan, Henry , Pusztai, Lajos , Euhus, David , Nanda, Rita , Elias, Anthony D , Clark, Amy S , Godellas, Constantine , Boughey, JC , Isaacs, Claudine , Tripathy, Debasish , Lu, Janice , Yung, Rachel L , Gallagher, Rosa I , Wulfkuhle, Julia D , Brown-Swigart, Lamorna , Krings, Gregor , Chen, Yunn Yi , Potter, David A , Stringer-Reasor, Erica , Blair, Sarah L , Asare, Smita M , Wilson, Amy , Hirst, Gillian L , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L , Berry, Scott , Asare, Adam L , Matthews, Jeffrey B , DeMichele, Angela , Hylton, Nola M. , Melisko, Michelle , Perlmutter, Jane , Rugo, Hope S , Symmans, W Fraser , Yee, Douglas , Berry, Donald , Esserman, Laura J , Pusztai, Lajos , Elias, Anthony , Boughey, Judy C. , Isaacs, Claudine , Gallagher, Rosa I. , Swigart, Lamorna Brown , Asare, Adam L. , DeMichele, Angela , Rugo, Hope S. , Esserman, Laura J.

Mayo Clinic

Clinical Cancer Research | December 18, 2023 | Volume: 30 | Issue: 4 | Pages: 729-740

10.1158/1078-0432.ccr-22-2256 | PMID 38109213 Get It

Abstract Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients and Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction. Results: There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease. Conclusions: The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority &gt;90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.